Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 317.1% in April

Allarity Therapeutics, Inc. (NASDAQ:ALLR) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 105,100 shares, a growth of 317.1% from the March 31st total of 25,200 shares. Approximately 25.0% of the company’s shares are sold short. Based on an average daily trading volume, of 497,100 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Allarity Therapeutics stock. Sabby Management LLC purchased a new position in shares of Allarity Therapeutics, Inc. (NASDAQ:ALLR) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 359,400 shares of the company’s stock, valued at approximately $268,000. Allarity Therapeutics makes up approximately 0.2% of Sabby Management LLC’s holdings, making the stock its 21st biggest holding. Sabby Management LLC owned approximately 13.16% of Allarity Therapeutics at the end of the most recent quarter. Institutional investors own 11.53% of the company’s stock.

Allarity Therapeutics Stock Performance

Shares of ALLR stock opened at $1.43 on Friday. The company’s 50-day simple moving average is $5.71 and its two-hundred day simple moving average is $8.88. Allarity Therapeutics has a one year low of $1.27 and a one year high of $415.92.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.